Orange Health Labs: US$30m Series C
An Orange Health Labs phlebotomist with a patient Source: Orange Health Labs website
Independent report content
| ROUND | Series C · US$30m (₹277 crore) · reported May–June 2026 |
|---|---|
| LEAD | Iron Pillar (about ₹156 crore) |
| EXISTING INVESTORS | Bertelsmann, Accel India, General Catalyst |
| NEW INVESTORS | Crescent Enterprises, Good Capital, Paramark Frontier Fund |
| FILING | 4,579,270 Series C CCPS at ₹604.72 each |
| EARLIER FUNDING | Nearly US$50m: Series B US$25m (2022, General Catalyst, Bertelsmann); US$12m (2024, Amazon Sambhav Venture Fund) |
| REVENUE | FY24 ₹49.4 crore · FY25 ₹84–88 crore · FY26 ₹138.6 crore (+65%) |
| LOSS | FY25 net loss ₹81.2 crore · FY26 loss before tax ₹97 crore |
| THE ACCESS POINT Orange Health is private. The Series C was taken by funds. Individuals can reach it only through those funds or rare secondaries. |
|---|
Executive decision summary
| THE BOTTOM LINE Orange Health Labs sends a phlebotomist to your home and promises blood-test results the same day, from its own labs. Revenue rose 65% to ₹138.6 crore in FY26 and the Series C of US$30m gives it room to expand. It still spent about ₹1.73 for every ₹1 earned, and loss before tax widened to ₹97 crore. Diagnostics is a business of density and volume: it works when each collector and lab handles many tests a day. |
|---|
| WHICH INVESTOR Fits you IF you want exposure to Indian consumer diagnostics growing faster than the chains and can accept losses for several years. Look elsewhere IF you want profitable diagnostics now; Dr Lal PathLabs, Metropolis and Thyrocare are listed and profitable. |
|---|
| COMFORT FIT Orange Health = a home-delivery service for blood tests. Dr Lal PathLabs, Metropolis, Thyrocare = the listed diagnostics chains. Healthians, Redcliffe, Tata 1mg Labs = other home-collection rivals. |
|---|
| THE RUPEIA NUMBER ₹1.73 spent per ₹1 earned in FY26, on revenue of ₹138.6 crore. |
|---|
1 CLAIM REGISTER: EVIDENCE GRADING
A = government or regulator record. B = statutory filing. C = independent press. D = company announcement.
| Claim | Source | Grade | Rupeia assessment |
|---|---|---|---|
| US$30m Series C led by Iron Pillar | Dealroom; Venture Intelligence; StartupResearcher | C | Established; date reported as May or June 2026. |
| 4,579,270 CCPS at ₹604.72 = ₹277 crore | Regulatory filings as reported | B/C | Established. |
| FY26 revenue ₹138.6 crore; loss before tax ₹97 crore | Ascendants; Indian Retailer | B/C | Established. |
| FY25 revenue ₹84–88 crore | Inc42; Indian Retailer | C | Outlets differ. |
2 COMPANY OVERVIEW & FOUNDING STORY
Orange Health Labs is a Bengaluru diagnostics company that offers fast, at-home blood tests in a market where most samples are collected at labs. A trained phlebotomist arrives, usually within a short slot, and results come the same day. It runs its own labs and has added collection centres in some cities.
3 TIMELINE
| Date | Event |
|---|---|
| 2022 | US$25m Series B |
| 2024 | US$12m round led by Amazon Sambhav Venture Fund |
| FY25 | Revenue about ₹87.7 crore |
| FY26 | Revenue ₹138.6 crore |
| May–Jun 2026 | US$30m Series C led by Iron Pillar |
4 FUNDING HISTORY & INVESTOR BEHAVIOUR
| Date | Round | Amount | Investors |
|---|---|---|---|
| 2022 | Series B | US$25m | General Catalyst, Bertelsmann |
| 2024 | Round | US$12m | Amazon Sambhav Venture Fund |
| 2026 | Series C | US$30m (₹277 crore) | Iron Pillar (lead, ~₹156 crore); Bertelsmann, Accel, General Catalyst; Crescent, Good Capital, Paramark |
Total capital raised is now about US$80m. Insiders all returned, which helps credibility.
| RUPEIA CALCULATION ₹277 crore from 4,579,270 shares at ₹604.72. Iron Pillar's about ₹156 crore is 56% of the round. The company has not published a valuation. |
|---|
5 FINANCIAL FORENSICS
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹49.4 crore | ₹84–88 crore | ₹138.6 crore |
| Growth | +77% | +65% | |
| Loss before tax | n/a | ₹87.4 crore | ₹97 crore |
| Loss % of revenue | n/a | ~100% | 70% |
Loss as a share of revenue fell from about 100% to 70% in a year, a solid improvement. In absolute terms the loss grew 11%.
6 BUSINESS MODEL & UNIT ECONOMICS
| Line | How it earns | Pressure point |
|---|---|---|
| Home collection tests | Fee per test package | Collector utilisation; cost per visit |
| Lab processing | Own labs process samples | Lab throughput |
| Collection centres and B2B | Walk-ins and partners | Capex |
| Health packages and subscriptions | Bundled tests | Repeat rates |
The key metric is revenue per collector per day. If a collector does more visits per slot, margins improve quickly.
7 MARKET & COMPETITIVE ANALYSIS
| Peer | Status | Position |
|---|---|---|
| Dr Lal PathLabs | Listed | Largest chain; profitable |
| Metropolis | Listed | Chain with B2B focus |
| Thyrocare | Listed | Pan-India low-price tests |
| Healthians, Redcliffe Labs, Tata 1mg Labs | Private | Home-collection rivals |
| Apollo Diagnostics | Listed parent | Hospital-linked chain |
8 VALUATION ANALYSIS
| Basis | Figure |
|---|---|
| Published valuation | None |
| ₹277 crore at 15–20% stake | ₹1,385–1,850 crore post-money (illustration) |
| Multiple of FY26 revenue | 10–13x |
Rupeia arithmetic only. Listed chains trade on profits, so any private price for Orange is a bet on scale.
9 SCENARIO ANALYSIS
| Scenario | Probability | What happens |
|---|---|---|
| Bull | 25% | Revenue passes ₹250 crore by FY28 with breakeven in sight |
| Base | 50% | Revenue grows 40–50%; losses narrow slowly |
| Bear | 25% | Competition from chains and Tata 1mg slows growth |
10 RISK ANALYSIS: RED FLAG LEDGER & KILL CONDITIONS
| Risk | Severity | Kill condition |
|---|---|---|
| Losses | High | FY27 loss above ₹100 crore |
| Competition and price cuts | High | Packages discounted by rivals |
| Quality and accreditation | Medium | A NABL or sample-handling incident |
| Unit economics | Medium | Cost per visit not falling |
11 INVESTOR CLASS ANALYSIS
HNIs and family offices
Access to Orange Health Labs is through its funds, a negotiated co-investment or the unlisted market where one exists. Price any offer against the latest round or filing.
Institutions
Strategic and institutional investors set the price; follow their disclosures.
NRIs
NRIs can hold unlisted Indian shares under FEMA pricing and reporting rules; repatriation depends on the account route used.
12 THE EARLY SIGNAL: EVENTS TO WATCH
| When | Event |
|---|---|
| 2027 | FY26 accounts and Series C valuation filings |
| 2027 | New cities and labs |
| 2027–28 | Breakeven target |
13 RUPEIA FINAL INDEPENDENT VIEW
Orange Health is growing faster than the chains and has narrowed its loss ratio. It still burns cash in a business that listed peers run at 20% margins.
| THE RUPEIA NUMBER ₹1.73 spent per ₹1 earned in FY26, on revenue of ₹138.6 crore. |
|---|
| RUPEIA VERDICT A good consumer diagnostics name with a long path to profit. Suitable for growth-fund style capital. |
|---|
Frequently asked questions
How much did Orange Health Labs raise?
US$30m (₹277 crore) in a Series C led by Iron Pillar in 2026.
What is its revenue?
₹138.6 crore in FY26, up 65%.
Is it profitable?
No. Loss before tax was ₹97 crore in FY26.
What does it do?
At-home blood tests with same-day results.
Source log
Dealroom: Orange Health Labs US$30m Series C
Venture Intelligence: Orange Health US$30m
Ascendants: Orange Health FY26
Indian Retailer: Orange Health FY26
Inc42: Orange Health financials
StartupResearcher: Orange Health Series C
| DISCLAIMER This report is independent research by Rupeia Investments Co. built only from public sources as of the date shown. It is not an offer, solicitation or investment advice, and it is not a recommendation to buy or sell any security. Private-company figures are drawn from filings and media reports and may be revised. Unlisted and private-market investments are illiquid and carry a risk of total loss. Investors should take independent advice. |
|---|
